MIT researchers have designed a wearable ultrasound device that attaches to a bra and could be used to detect early-stage breast tumors, reports Lizzy Lawrence for STAT. “I’m hoping to really make it real, and to touch people’s lives,” says Prof. Canan Dagdeviren. “I want to see the impact of my technology not only in the lab, but on society.”
Writing for The Washington Post, research affiliate Bina Venkataraman emphasizes that “if biomedical breakthroughs are to benefit the millions of children afflicted with rare diseases, genetic testing of babies needs to expand.” Venkataraman adds: “By screening newborn genomes for currently known genetic diseases, patients and scientists could gain insights that lead to the treatment and prevention of thousands of illnesses that currently lack cures.”
Researchers at MIT have developed a mobile vaccine printer capable of printing a vaccine onto a patch of microneedles that can be absorbed into the skin without injection, reports Sandra Tsing for NPR. “These printed vaccines could be used in areas that are unable to refrigerate traditional vaccines,” explains Tsing.
Prof. Daniela Rus, director of CSAIL, writes for Forbes about Prof. Dina Katabi’s work using insights from wireless systems to help glean information about patient health. “Incorporating continuous time data collection in healthcare using ambient WiFi detectable by machine learning promises an era where early and accurate diagnosis becomes the norm rather than the exception,” writes Rus.
Researchers from MIT and Massachusetts General Hospital have developed “Sybil,” an AI tool that can detect the risk of a patient developing lung cancer within six years, reports Mary Kekatos for ABC News. “Sybil was trained on low-dose chest computer tomography scans, which is recommended for those between ages 50 and 80 who either have a significant history of smoking or currently smoke,” explains Kekatos.
In an article for Forbes, research affiliate John Werner spotlights Prof. Dina Katabi and her work showcasing how AI can boost the capabilities of clinical data. “We are going to collect data, clinical data from patients continuously in their homes, track the symptoms, the evolution of those symptoms, and process this data with machine learning so that we can get insights before problems occur,” says Katabi.
Michael Goldberg PhD '08 founded Surge Therapeutics, a company developing a hydrogel immunotherapy treatment aimed at reducing the risk of surgically-removed cancers returning, reports India Rice for Forbes. “Broadly speaking, immunotherapy is a range of cancer treatments that aim to strengthen the immune system’s ability to fight cancer,” explains Rice. “But what makes Surge’s solution different is that it’s applied during surgery as opposed to other immunotherapies that are delivered weeks before or weeks after surgery.”
Prof. Regina Barzilay speaks with Nicole Estephan of WCVB-TV’s Chronicle about her work developing new AI systems that could be used to help diagnose breast and lung cancer before the cancers are detectable to the human eye.
Prof. Jon Gruber speaks with Boston Public Radio hosts Jim Braude and Margery Eagen about the economics behind the Ozempic phenomenon, an antidiabetic drug being used to manage weight loss. “This is very new phenomenon and I think we are just starting to grapple with it,” says Gruber. “I think one positive aspect… it will put pressure on Congress to once again think more seriously about broader price of drug reform.”
Prof. Kevin Esvelt and his students have found that language-generating AI models could make it easier to create pandemic potential pathogens, reports Kelsey Piper for Vox.
MIT researchers and an undergraduate class found that chatbots could be prompted to suggest pandemic pathogens, including specific information not commonly known among experts, reports Ryan Health for Axios. The MIT researchers recommend "pre-release evaluations of LLMs by third parties, curating training datasets to remove harmful concepts, and verifiably screening all DNA generated by synthesis providers or used by contract research organizations."
Science reporter Robert F. Service spotlights how Prof. Kevin Esvelt is sounding the alarm that “AI could help somebody with no science background and evil intentions design and order a virus capable of unleashing a pandemic.”
Researchers at MIT have developed an ingestible pill that can raise levels of hormones to help increase appetite and decrease nausea, reports Maggie Chen for Wired. The researchers “hope that it can one day act as an effective noninvasive therapy for those who experience gastroparesis—or other eating disorders—essentially being a temporary switch that can be activated to drive hunger and digestion,” writes Chen.
Prof. Marzyeh Ghassemi speaks with NPR host Kate Wells about a decision by the National Eating Disorders Associations to replace their helpline with a chatbot. “I think it's very alienating to have an interactive system present you with irrelevant or what can feel like tangential information,” says Ghassemi.
Principal Research Scientist Ana Jaklenec speaks with CBC host Bob McDonald about her work developing a mobile vaccine printer. The device “can be very important in certain scenarios when you’re trying to bring the ability to vaccinate in areas that might not have the right infrastructure to make vaccines or even to administer vaccines,” says Jaklenec, “so I think the portability is key here.”